ASH 2026 Exhibitors
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
271 organizations exhibit at ASH 2026 — 105 suppliers and service providers, 86 pharma and biotech companies, 51 government and non-profit bodies and 29 hospitals and cancer centres. 17 of them also present on the scientific program, with 36 presentations between them. Most represented: MD Anderson Cancer Center (16 on the program), Moffitt Cancer Center (10 on the program), Children's Hospital of Philadelphia (8 on the program). 271 of them have their own page in this guide. As of Sep 27, 2026.
Topic
Top represented
Showing 1–30 of 271 organizations
| Organization | ASH 2026 Attendance |
|---|---|
MD Anderson Cancer Center Houston, TX | |
NCI-designated comprehensive cancer center of the University of Texas in Houston, focused on cancer care, research and clinical trials. | Booth Exhibiting at Booth 2857 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00pm–10:00pm Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms CAR-T as standard lymphoma care and what comes next, including dual-target, faster-manufactured, and in vivo versions that could widen patient access. Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum Using molecular subtypes of diffuse large B-cell lymphoma to choose frontline treatment among polatuzumab regimens, bispecific antibodies, and CAR-T. Symposium Fri Dec 11 3:00pm–6:00pm Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era Ordering acute lymphoblastic leukemia therapies, from asparaginase to bispecifics and CAR-T, guided by sensitive residual disease testing. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects. Talk Phenotypes and Specificities of AML/MDS-Associated T Cell Populations What T cells in leukemic and pre-leukemic bone marrow look like, where they sit, and which are worn out, guiding biomarkers and new immunotherapies. Talk Trm Phenotype and Functions How T cells come to reside permanently in tissues during infection and cancer, how to study them, and therapies that harness them. Talk Future of Targeted Therapies in AML Where acute myeloid leukemia treatment is heading, from new chemotherapy backbones and targeted drug pairings to next-generation drugs that overcome resistance. Talk |
Moffitt Cancer Center Tampa, FL | |
NCI-designated comprehensive cancer center in Tampa, Florida, working on cancer prevention, treatment, research and training. | Booth Exhibiting at Booth 3623 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 11:00am–2:00pm CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life First-line drug choice, resistance, long-term side effects, and treatment-free remission in chronic myeloid leukemia, plus pipeline agents. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Session Are We There Yet? Improving Outcomes in MDS Assessing and treating myelodysplastic syndromes, marrow failure cancers of older adults that can turn into acute myeloid leukemia, using newer risk systems. Session Medical Educators' Symposium Practical strategies for medical educators on time management, wellness, inclusive learning spaces, and teaching with AI, apps, and social media. |
Children's Hospital of Philadelphia Philadelphia, PA | |
Pediatric hospital and research institute in Philadelphia, with major programs in pediatric hematology, sickle cell disease and cell and gene therapy. | Booth Exhibiting at Booth 2221 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs. Talk Lipid Nanoparticle (LNP) Delivery to Hematopoietic Stem Cells in Vivo Delivering mRNA and gene editors to blood stem cells inside the body with lipid nanoparticles, including editing before birth for inherited blood diseases. Talk Unmet Needs in Transfusion Medicine: Alloimmunization, Rare Blood Types, and the Case for Lab-Grown Red Cells Patients with rare blood types or antibodies against donor red cells struggle to find matches, and engineered lab-grown cells could supply tailored units. Talk Heparin-Induced Thrombocytopenia (HIT): How Heparin Sparks Thrombosis How the blood thinner heparin binds a platelet protein and provokes antibodies that drop platelet counts and paradoxically cause dangerous clots. Session Iron Homeostasis Across the Lifespan in Health and Disease Iron balance from fetal life to old age, what goes wrong in deficiency and overload, and the pathways being targeted to treat iron-related disorders. Session Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes Genomic tools and better disease models are changing how inherited blood disorders in children are found, understood, and managed. Session The Future of Clinical Endpoints in Sickle Cell Disease Better sickle cell disease trial endpoints than pain-crisis counts, such as biomarkers, combined measures, and patient-reported outcomes reflecting daily burden. |
Roswell Park Comprehensive Cancer Center Buffalo, NY | |
NCI-designated comprehensive cancer center in Buffalo, New York, founded in 1898, offering transplant, CAR T-cell therapy and cancer research. | Booth Exhibiting at Booth 2557 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care Sequencing CAR-T and T-cell engagers for relapsed myeloma, when to refer, managing toxicity, and options after B-cell maturation antigen therapy fails. Symposium Fri Dec 11 3:00pm–6:00pm Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors Menin inhibitors for genetically defined acute myeloid leukemia, covering patient selection, combinations, resistance, and differentiation syndrome. Session A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation How donor stem cell transplants became safer and more widely available, through better graft-versus-host disease prevention, new treatments, and more donor options. Talk Donor for All: Increasing Access and Improving Outcomes Expanding donor options with mismatched unrelated, half-matched family, and umbilical cord blood transplants, and evidence that outcomes hold up across donor types. |
St. Jude Children's Research Hospital Memphis, TN | |
Pediatric research hospital in Memphis focused on childhood cancer, combining laboratory research, clinical trials, patient care and training. | Booth Exhibiting at Booth 2824 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs. Talk Regulation of HSCs by the Adaptive Immune System How T cells and other adaptive immune cells recognize and clear mutant blood stem cells, and harnessing this to prevent premalignant clonal expansion. Talk Escape Clones in Immune Mediated BMF How blood stem cells in aplastic anemia dodge attacking T cells by disabling a tissue-type gene, repeatedly and independently, years before diagnosis. Talk Metabolic Switches Underpin Erythropoiesis A link between glutamine handling and heme production in maturing red cells, and how losing that detoxifying step goes wrong in beta-thalassemia. Talk Dissecting the Functional Consequence of Non-Coding Variants How CRISPR screens and single-cell methods show the way non-coding DNA variants alter gene regulation in acute lymphoblastic leukemia. Talk CAR T-Cell Therapy in Pediatric AML: Current Limitations and Emerging Opportunities Barriers facing CAR-T therapy in childhood acute myeloid leukemia and how multi-target designs and tumor-environment combinations might overcome them. Session Innovations in the Treatment of Pediatric AML How gene-fusion biology in childhood acute myeloid leukemia is shaping targeted and antibody-drug conjugate treatments beyond standard chemotherapy. Talk Integrating Newborn Screening for SCD by CONSA, St Jude's Global Hematology and Ministries of Health into PEN-Plus in LMICs and Rural Settings Adding newborn sickle cell disease screening to chronic disease care in low-resource and rural regions, drawing on a Mozambique case study. |
Fred Hutch Cancer Center Seattle, WA | |
Independent nonprofit cancer research and treatment center in Seattle; Washington's only NCI-designated cancer center. | Booth Exhibiting at Booth 2319 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 3:00pm–6:00pm Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care Sequencing CAR-T and T-cell engagers for relapsed myeloma, when to refer, managing toxicity, and options after B-cell maturation antigen therapy fails. Symposium Fri Dec 11 3:00pm–6:00pm ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care Personalizing immune thrombocytopenia care beyond platelet counts, weighing new therapies alongside fatigue, cognition, heavy periods, and quality of life. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects. Talk Viral Vector-Mediated In Vivo Hematopoietic Stem Cell Gene Therapy: Targets, Delivery, and Selection Delivering gene therapy to blood stem cells with viral vectors, plus surface marker edits that let corrected cells be enriched inside the body. |
NCI-designated comprehensive cancer center of Ohio State University in Columbus, including its dedicated cancer hospital. | Booth Exhibiting at Booth 2539 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL Continuous kinase inhibitors versus fixed-duration Bcl-2 combinations for chronic lymphocytic leukemia, weighed against recent phase 3 trial results. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 11:00am–2:00pm Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making Using tests for isocitrate dehydrogenase and Flt3 mutations to guide targeted therapy choices in acute myeloid leukemia. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Talk Practical Generative AI Tools for Clinicians and Investigators Using generative AI in hematology clinics and labs, from prompt writing to literature review, coding and data analysis, while protecting data privacy. Session Treating Fairly Rounds Lunch How hematologists and fellows can influence healthcare reform on research funding, Medicaid, and hospital budgets, and how policy shapes health inequities. |
City of Hope Duarte, CA | |
Cancer and diabetes research and treatment center founded in 1913 in Duarte, California, offering transplant, CAR T-cell therapy and clinical trials. | Booth Exhibiting at Booth 3423 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 7:00pm–10:00pm Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL Continuous kinase inhibitors versus fixed-duration Bcl-2 combinations for chronic lymphocytic leukemia, weighed against recent phase 3 trial results. Symposium Fri Dec 11 3:00pm–6:00pm Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence Tailoring four-drug frontline regimens for newly diagnosed myeloma using residual disease testing, transplant criteria, and new ways of giving treatment. Talk Coming to Trms with GVHD Tissue-resident memory T cells that sustain chronic graft-versus-host disease, the stem-like and progenitor subsets in target organs, and how they mature. |
Cleveland Clinic Cleveland, OH | |
Nonprofit academic medical center in Cleveland, Ohio; its Taussig Cancer Institute offers blood cancer care, stem cell transplant and CAR T-cell therapy. | Booth Exhibiting at Booth 131 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Talk Role of Inflammasome Inhibitors in the Intersection of CH and Thrombosis Drugs that block the inflammasome and interleukin-1 signaling as a way to prevent clots and heart disease in people with clonal hematopoiesis. Session Balancing Bleeding and Clotting: Extended VTE Treatment for Whom and at What Dose? Longer-term anticoagulation for cancer-associated blood clots after the first six months, using new randomized trials to guide who continues and at what dose. |
Rutgers Cancer Institute New Brunswick, NJ | |
New Jersey's NCI-designated comprehensive cancer center, run with RWJBarnabas Health, offering cell therapy, stem cell transplant and clinical trials. | Booth Exhibiting at Booth 1923 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. |
Veterans Health Administration Washington, DC | |
US Department of Veterans Affairs health system, running VA medical centers and clinics nationwide and recruiting clinicians. | Booth Exhibiting at Booth 2819 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
AstraZeneca Cambridge, United Kingdom | |
Global biopharmaceutical company; hematology medicines include the BTK inhibitor acalabrutinib for CLL and mantle cell lymphoma. | Booth Exhibiting at Booth 1339 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum Using molecular subtypes of diffuse large B-cell lymphoma to choose frontline treatment among polatuzumab regimens, bispecific antibodies, and CAR-T. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. |
Novartis Basel, Switzerland | |
Swiss pharmaceutical company with hematology medicines spanning CML, immune thrombocytopenia, myelofibrosis and CAR T-cell therapy. | Booth Exhibiting at Booth 2339 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00am–10:00am B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice Newer B-cell-targeting treatments for immune thrombocytopenia and how to fit them into care to achieve lasting platelet responses. Symposium Fri Dec 11 11:00am–2:00pm CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life First-line drug choice, resistance, long-term side effects, and treatment-free remission in chronic myeloid leukemia, plus pipeline agents. Symposium Fri Dec 11 3:00pm–6:00pm Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum Getting relapsed lymphoma patients to CAR-T sooner, with earlier referral, bridging therapy, sequencing choices, and management of immune and nerve toxicities. |
Regeneron Tarrytown, NY | |
Biotechnology company developing antibody medicines, including bispecific antibodies for multiple myeloma and non-Hodgkin lymphoma. | Booth Exhibiting at Booth 1229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows. Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Session T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics Memory T cells that stay put in tissues drive chronic inflammation after infection, in tumors, and after transplant, and the pathways keeping them alive. |
Penn Medicine Philadelphia, PA | |
University of Pennsylvania's academic health system; its Abramson Cancer Center provides cancer care across hospitals in Pennsylvania, New Jersey and Delaware. | Booth Exhibiting at Booth 130 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Session Real-World Data Applications in Sickle Cell Disease Trial Design Using sickle cell disease registries and health records to build external control arms, track safety after approval, and define pain as a trial endpoint. |
Agios Pharmaceuticals Cambridge, MA | |
Commercial-stage biopharmaceutical company with roots in hematology, developing medicines for rare diseases. | Booth Exhibiting at Booth 929 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. |
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company; its rare disease unit develops treatments for hemophilia and other rare blood disorders, including sickle cell disease. | Booth Exhibiting at Booth 913 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. |
Advocate Health Charlotte, NC | |
Nonprofit US health system formed by Advocate Aurora Health and Atrium Health, running hospitals across the Midwest and Southeast. | Booth Exhibiting at Booth 122 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies Treating primary central nervous system lymphoma, from methotrexate-based induction and consolidation choices to new drugs aimed at its signaling mutations. |
CLL Society Chula Vista, CA | |
Non-profit for people with CLL and SLL, providing patient education, advocacy, support and research grants, plus free materials for clinicians. | Booth Exhibiting at Booth 2914 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. |
John Theurer Cancer Center Hackensack, NJ | |
Cancer center of Hackensack University Medical Center, New Jersey's largest, offering cancer diagnosis, treatment, transplant, research and survivorship care. | Booth Exhibiting at Booth 2015 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. |
OHSU Knight Cancer Institute Portland, OR | |
NCI-designated comprehensive cancer center at Oregon Health & Science University in Portland, for cancer research, care and education. | Booth Exhibiting at Booth 2523 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making Using tests for isocitrate dehydrogenase and Flt3 mutations to guide targeted therapy choices in acute myeloid leukemia. |
Pfizer New York, NY | |
Global pharmaceutical company whose hematology portfolio spans myeloma, leukemia and hemophilia medicines. | Booth Exhibiting at Booth 2039 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Sarah Cannon Research Institute Nashville, TN | |
Oncology research organization running cancer clinical trials in community settings for more than 30 years. | Booth Exhibiting at Booth 2316 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. |
Bristol Myers Squibb Princeton, NJ | |
Global biopharmaceutical company with hematology medicines in myeloma, lymphoma, leukemia and anemia, including CAR T-cell therapies. | Booth Exhibiting at Booth 1313 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading. Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Symposium Fri Dec 11 11:00am–2:00pm The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing. |
Sanofi Paris, France | |
Global healthcare company developing medicines and vaccines, with teams in around 100 countries. | Booth Exhibiting at Booth 2939 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Hemophilia at the Crossroads: New Evidence for Individualized Care Tailoring hemophilia prevention with factor replacement, factor-mimicking drugs, rebalancing agents, and gene therapy to protect joints and ease treatment burden. Symposium Fri Dec 11 3:00pm–6:00pm ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care Personalizing immune thrombocytopenia care beyond platelet counts, weighing new therapies alongside fatigue, cognition, heavy periods, and quality of life. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence Tailoring four-drug frontline regimens for newly diagnosed myeloma using residual disease testing, transplant criteria, and new ways of giving treatment. Symposium Fri Dec 11 11:00am–2:00pm Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice Newly diagnosed multiple myeloma care in community clinics, using frailty assessment, dose adjustment to protect quality of life, and new drug formulations. |
Decera Clinical Education Reston, VA | |
Accredited medical education company (Clinical Education Alliance) running clinician education programs and satellite symposia, with data and market-research services. | Booth Exhibiting at Booth 2123 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. |
Johnson & Johnson New Brunswick, NJ | |
Global healthcare company that develops, makes and sells prescription medicines and medical technologies, including myeloma and other blood cancer therapies. | Booth Exhibiting at Booth 2913 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows. Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Symposium Fri Dec 11 3:00pm–6:00pm Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors Menin inhibitors for genetically defined acute myeloid leukemia, covering patient selection, combinations, resistance, and differentiation syndrome. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. |
BeOne Medicines Basel, Switzerland | |
Global oncology company, formerly BeiGene, whose medicines include the BTK inhibitor zanubrutinib for CLL and other B-cell cancers. | Booth Exhibiting at Booth 421 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. |
Lilly Indianapolis, IN | |
Global pharmaceutical company based in Indianapolis whose oncology portfolio includes the BTK inhibitor pirtobrutinib for CLL and mantle cell lymphoma. | Booth Exhibiting at Booth 1039 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL Continuous kinase inhibitors versus fixed-duration Bcl-2 combinations for chronic lymphocytic leukemia, weighed against recent phase 3 trial results. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. |
AbbVie North Chicago, IL | |
Global biopharmaceutical company discovering and developing medicines for serious diseases across several therapeutic areas, including blood cancers. | Booth Exhibiting at Booth 1613 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. |
Instantly find 20 buyers from ASH 2026 exhibitors
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
- Exhibitors 271
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction